The Lusys Laboratories Covid-19 Antigen Test
Lusys Laboratories Covid-19 Antigen Test: The U.S. Food and Drug Administration (FDA) is warning people to cease using LuSys Laboratories COVID-19 Antigen Test (Nasal/Saliva) as well as the LuSys Laboratories COVID-19 IgG/IgM Antibody Test. The effectiveness of these tests has still not been thoroughly established and also the FDA feels there’s really likely a substantial risk of incorrect results when utilising these tests. None test has indeed been approved, certified, or approved by fda for distribution and use in the United States.
The LuSys Laboratories COVID-19 Antigen Tests (Nasal/Saliva) or COVID-19 IgG/IgM Antibody Tests may alternatively be sold under the corporate names Luscient Diagnostics and Vivera Pharmaceuticals, or with the trade name EagleDx. The FDA believes that all these tests were provided for use in laboratories or even for at-home testing.
Recommendations For Test Users, Caregivers, And Health Care Personnel
Stop utilising the COVID-19 Antigen Tests (Nasal/Saliva) & COVID-19 IgG/IgM Antibody Tests by LuSys Laboratories.
Covid-19 Antigen Test (Nasal/Saliva)
Test users and caregivers: If you have questions or concerns about the findings of your LuSys Laboratories COVID-19 Antigen Test (Nasal/Saliva), you should consult your physician.
Health care personnel: Retesting your patients with a separate SARS-CoV-2 diagnostic test may be necessary if the antigen test is given or less than two weeks ago and you suspect an incorrect result. Retesting is not indicated in cases where testing was done or more two weeks ago and no current SARS-CoV-2 infection is suspected.
The FDA should be notified of any issues you have with the LuSys Laboratories COVID-19 Antigen Tests (Nasal/Saliva), including possible misleading findings. Problems with your test? Here’s how to report them.
Covid-19 Igg/Igm Antibody Test
Test users and caregivers: If you’re concerned about your test results from the LuSys COVID-19 IgG/IgM Antibody Test, contact your doctor. Health care personnel:
Patients who have recently or previously had a COVID-19 infection should be retested using a new SARS-CoV-2 antibody test.
Any issues you have with the LuSys COVID-19 IgG/IgM Antibody Test, including misleading findings, should be reported to the FDA, See Troubleshooting Your Test for further information.
Descriptions Of Tests
It is possible to detect antigens from the SARS-CoV-2 virus using a nasal or saliva sample in the LuSys Laboratories’ COVID-19 Antigen Test (Nasal/Saliva).
In order to perform the COVID-19 Antibody Test, LuSys Laboratories need serum, plasma or blood samples. Immunoglobulin testing aims to identify antibodies produced by a person’s body’s response to SARS-CoV-2 (the SARS virus that produces COVID-19), which indicates recent or past infection. An active infection with COVID-19 cannot be diagnosed or excluded using antibody testing.
Other names for LuSys Laboratories’ COVID-19 antigen and antibody tests include: Luscient Diagnostics, Vivera Pharmaceuticals, and EagleDx, among others. According to the FDA, these tests were either given out to laboratories or given out to consumers.
Potential Risk Of False Test Results
Lusys Laboratories Covid-19 Antigen Test (Nasal/Saliva):
An antigen test result that indicates that a person is not infected with COVID-19 is a false-negative result. Incorrect diagnosis or treatment of SARS-CoV-2 may result in significant disease and death if a false-negative result is obtained. Additionally, patients may be put together in healthcare coverage, long-term care, or other settings based on false-negative test findings, which can further spread the SARS-CoV-2 virus. It’s possible that preventative measures like isolating people, limiting interaction with loved ones, or restricting access to work won’t be taken if false negative test results are received.
Testing for COVID-19 antigen yields false-positive results when the individual tested negative for the virus. For example, a false-positive may delay the accurate diagnosis and treatment for a person’s illness, which is another life-threatening disease which is not COVID-19. SARS-CoV-2 virus could spread much further if false-positive results are combined into cohorts of supposed positive patients (that is, they are housed together).
Lusys Laboratories Covid-19 Igg/Igm Antibody Test:
Lusys Laboratories Covid-19 Antigen Test: Test findings that indicate a person does not even have antibodies to a SARS-CoV-2 virus when they actually do are known as false-negative antibody results (FNA). If the test is used incorrectly to detect an active infection or whether the test result is misconstrued to suggest that the user did not really have a recent infection, false-negative results would lead to fewer precautions being taken to avoid the spread of infection.
Testing for SARS-CoV-2 virus antibodies can yield false-positive or false-negative findings, depending on whether or not the individual genuinely has antibodies to a SARS-CoV-2 virus. Because of the risk of false-positive results, SARS-CoV-2 test users may not take as many precautions as they need to prevent themselves from future SARS-CoV-2 infections.